noticias

Companies

Ingenza welcomes Ian Shott as its new Executive Chairman

Edinburgh-based Ingenza, a pioneer in engineering biology, is pleased to announce the appointment of Dr Ian Shott CBE, FREng to the board as Executive Chairman. Ian joins Ingenza with over 35 years of experience in the global life science and biotechnology industries and is Executive Chairman of Shott Trinova, a specialist advisory and investment firm focused on helping a portfolio of life science businesses accelerate their growth and performance. Ian was the co-founder and CEO of Arcinova –a UK-based pharmaceutical contract development and manufacturing organisation (CDMO)– which was sold to Quotient Sciences in 2021. Prior to this, he founded Excelsyn –a business specialising in chemical development and manufacturing services for the pharmaceutical industry– which he sold to AMRI in 2010. He has also held several global leadership positions with multinational life science companies including AstraZeneca, Lonza and Rhodia, where he has led the formulation and implementation of highly successful step change growth strategies. In parallel to his business activities, Ian is closely involved in the leadership of several industry bodies and business-university collaborations, ensuring he is perfectly placed to advise Ingenza as the company enters a new growth phase.

Ian commented: “Ingenza has an excellent history of technology invention, innovation, and development for both small and large companies. It has collaborated with universities and industry groups to continuously update, renew, and expand its technology platforms, and the company is now ideally positioned to move into a high growth phase. I have interacted with Ingenza on successful projects over the last two decades and am hugely excited to now join the company board to help drive this next phase of unbridled progress, with a particular focus on satisfying customers with unmet needs while simultaneously providing strong societal benefits.”

Ian Fotheringham, CEO at Ingenza, added: “I have had the pleasure of knowing and working closely with Ian Shott for over 20 years in numerous areas of biotechnology innovation, including its successful application

Awards

Eppendorf & Science Prize for Neurobiology 2023: Call for entries

The journal Science and Eppendorf are now accepting applications for the 2023 Eppendorf & Science Prize for Neurobiology. This annual international research prize of US$25,000 is awarded to young scientists for their outstanding contributions to neurobiological research based on methods of molecular and cell biology. Researchers not older than 35 years are invited to apply by June 15, 2023. The winner and finalists are selected by a committee of independent scientists, chaired by Science’s Senior Editor, Dr. Peter Stern. The 2022 prize was won by the American scientist Ann Kennedy, Ph.D., Assistant Professor at Northwestern University Feinberg School of Medicine, Chicago, for her research on brain activity underlying aggression.

Eppendorf is a life science company that develops and sells instruments, consumables, and services for liquid handling, sample handling, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermenters, bioreactors, CO2 incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microplates, and singleuse bioreactor vessels complement the range of highest-quality premium products. As digital solution, Eppendorf is developing new business models and transforming the Eppendorf portfolio to meet Industry 4.0 requirements. Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics, and at industrial laboratories performing process analysis, production, and quality assurance. within his businesses, collaborative programmes with leading academic teams, and within industry steering groups. Ian’s unique insight in maximising business growth through the strategic application of technology brings an enormous asset to Ingenza as we look forward to fully realising the benefits of engineering biology for human health and our planet’s future.”

Eppendorf was founded in Hamburg, Germany in 1945 and has about 5,500 employees worldwide. The company has subsidiaries in 26 countries and is represented in all other markets by distributors.

Jaymin Amin, Chief Business Officer at Ingenza, said: “We are delighted to welcome Ian Shott to the board as Executive Chairman. His appointment will be key to guiding the board in defining new growth strategies for the company. Ian’s unparalleled breadth of expertise in revolutionising small molecule manufacturing through a